BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 23385376)

  • 21. Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.
    Tedeschi A; Conticello C; Rizzi R; Benevolo G; Laurenti L; Petrucci MT; Zaja F; Varettoni M
    Hematol Oncol; 2019 Apr; 37(2):117-128. PubMed ID: 30192023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.
    Grunenberg A; Buske C
    Dtsch Arztebl Int; 2017 Nov; 114(44):745-751. PubMed ID: 29169431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders.
    Pangalis GA; Kyrtsonis MC; Kontopidou FN; Siakantaris MP; Dimopoulou MN; Vassilakopoulos TP; Tzenou T; Kokoris S; Dimitriadou E; Kalpadakis C; Tsalimalma K; Tsaftaridis P; Panayiotidis P; Angelopoulou MK
    Clin Lymphoma; 2005 Mar; 5(4):235-40. PubMed ID: 15794855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Waldenström's macroglobulinemia: treatment approaches for newly diagnosed and relapsed disease.
    Hodge LS; Ansell SM
    Transfus Apher Sci; 2013 Aug; 49(1):19-23. PubMed ID: 23773867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The epidemiology of Waldenström macroglobulinemia.
    McMaster ML
    Semin Hematol; 2023 Mar; 60(2):65-72. PubMed ID: 37099032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Waldenstrom's macroglobulinemia: Recent advances in biology and therapy.
    Neparidze N; Dhodapkar MV
    Clin Adv Hematol Oncol; 2009 Oct; 7(10):677-81, 687-90. PubMed ID: 20040909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
    Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
    N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Waldenström's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center.
    Merchionne F; Procaccio P; Dammacco F
    Crit Rev Oncol Hematol; 2011 Oct; 80(1):87-99. PubMed ID: 21036057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphoplasmacytic lymphoma with IgA paraproteinemia mimicking Waldenstrom's Macroglobulinemia.
    Basu D; Pathak D; Shyambabu C; Koner BC; Swaminathan RP
    Indian J Pathol Microbiol; 2004 Oct; 47(4):515-7. PubMed ID: 16295380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia.
    Schuster SR; Rajkumar SV; Dispenzieri A; Morice W; Aspitia AM; Ansell S; Kyle R; Mikhael J
    Am J Hematol; 2010 Nov; 85(11):853-5. PubMed ID: 20842638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diffuse interstitial lung disease as a first manifestation of Waldenström's macroglobulinemia: case report and review of the literature.
    Consuegra A; Marcos PJ; Vázquez R; Pombo J; Debén G; Verea-Hernando H
    Arch Bronconeumol; 2014 Apr; 50(4):151-3. PubMed ID: 24629759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis.
    Merlini G; Sarosiek S; Benevolo G; Cao X; Dimopoulos M; Garcia-Sanz R; Gatt ME; Fernandez de Larrea C; San-Miguel J; Treon SP; Minnema MC
    Semin Hematol; 2023 Mar; 60(2):113-117. PubMed ID: 37099030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IgM multiple myeloma: report of four cases and review of the literature.
    Annibali O; Petrucci MT; Del Bianco P; Gallucci C; Levi A; Foà R; Avvisati G
    Leuk Lymphoma; 2006 Aug; 47(8):1565-9. PubMed ID: 16966268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan].
    Sekiguchi N
    Rinsho Ketsueki; 2021; 62(8):1139-1148. PubMed ID: 34497201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Waldenström's macroglobulinemia: a review of therapy.
    Gertz MA
    Leuk Lymphoma; 2002 Aug; 43(8):1517-26. PubMed ID: 12400593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit.
    Kyrtsonis MC; Vassilakopoulos TP; Angelopoulou MK; Siakantaris P; Kontopidou FN; Dimopoulou MN; Boussiotis V; Gribabis A; Konstantopoulos K; Vaiopoulos GA; Fessas P; Kittas C; Pangalis GA
    Ann Hematol; 2001 Dec; 80(12):722-7. PubMed ID: 11797112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.
    Landgren O; Tageja N
    Leukemia; 2014 Sep; 28(9):1799-803. PubMed ID: 24573383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Waldenström's macroglobulinemia.
    McKenna JA
    Clin J Oncol Nurs; 2002; 6(5):283-6. PubMed ID: 12240489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.
    Naderi N; Yang DT
    Arch Pathol Lab Med; 2013 Apr; 137(4):580-5. PubMed ID: 23544948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.
    Mailankody S; Landgren O
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):187-193. PubMed ID: 27825465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.